Effect of antisense RNA targeting Polo-like kinase 1 on cell growth in A549 lung cancer cells

Abstract

In order to investigate the effect of Polo-like kinase-1 (Plk1) depletion on cell cycle progression and cell growth in lung cancer cells, a recombinant plasmid containing antisense RNA targeting Plk1 (pcDNA3-Plk1) was transfected into A549 cells by lipofectine. RT-PCR and Western-blot were used to detect the Plk1 gene expression. Cell proliferation was evaluated by direct cell counting and bromodeoxyuridine (BrdU) labeling. Cell cycle distribution and apoptosis were examined by flow cytometry, and the inhibition rate (IR) by vinorebline (NVB) was determined by MTT assay. The results showed that after transfection of pcDNA3-Plk1 into A549 cells, the expression levels of Plk1 mRNA and protein were greatly decreased. In pcDNA3-Plk1 transfected groups, abnormal morphological changes of cells and growth inhibition were observed, and the BrdU labeling index was significantly lower than in the control groups (P<0.05). Cells in pcDNA3-Plk1 transfected groups were arresed in G₂/M phase and apoptosis was detectable 72 h post transfection. IR induced by vinorebline in pcDNA3-Plk1 transfected groups was significantly higher than in other groups. These data suggested that antisense RNA targeting Plk1 could suppress the Plk1 expression, and therefore, significantly inhibit cell proliferation and induce cell cycle arrest and apoptosis. Moreover, it sensitized lung cancer cells to chemotherapy.

Keywords

Polo-like kinase-1 / antisense RNA / lung cancer / proliferation / cell cycle

References

[1] DonaldsonM. M., TavaresA. A., HaganI. M., et al.. The mitotic roles of Polo-like kinase. J Cell Sci, 2001, 114(Pt13): 2357-2358

[2] van VugtM. A., BrasA., MedemaR. H.. Restarting the cell cycle when the checkpoint comes to a halt. Cancer Res, 2005, 65(10): 7037-7040

[3] TakaiN., HamanakaR., YoshimatsuJ., et al.. Polo-like kinases (Plks) and cancer. Oncogene, 2005, 24(2): 287-291

[4] JungM., GrunbergS., TimblinC., et al.. Paclitaxel and vinorelbine cause synergistic increase in apoptosis but not in microtubular disruption in human lung adenocaconoma cells (A-549). Histochem Cell Biol, 2004, 121(2): 115-121

[5] van VugtM. A., SmitsV. A., KlompmarkerR., et al.. Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM-or ATR-dependent fashion. J Biol Chem, 2001, 276(45): 41 656-41660

[6] RoshakA. K., CapperE. A., ImburgiaC., et al.. The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal, 2000, 12(6): 405-411

[7] Toyoshima-MorimotoF., TaniguchiE., NishidaE.. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep, 2002, 3(4): 341-348

[8] LiuX., EriksonR. L.. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci, 2002, 99(13): 8672-8676

[9] van VugtM. A., Van De WeerdtB. C., VaderG., et al.. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem, 2004, 279(35): 36 841-36 854

[10] LiuX., EriksonR. L.. Polo-like kinase (plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acac Sci USA, 2003, 100(10): 5789-5794

[11] AndoK., OzakiT., YamamotoH., et al.. Polo-like kinase 1(Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem, 2004, 279(24): 25 549-25 561